🇺🇸 FDA
Patent

US 7892539

Modulation of an innate immune response by altering TRIAL-R signaling

granted A61KA61K38/00

Quick answer

US patent 7892539 (Modulation of an innate immune response by altering TRIAL-R signaling) held by The Regents of the University of California expires Mon Feb 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Feb 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K38/00